Developing and commercializing innovative drugs to treat cancer and orphan diseases and protect healthy tissues.Learn More
Our proprietary platform of toll-like immune receptor activators has applications in radiation mitigation, oncology immunotherapy, and vaccines.
Our most advanced product candidate is entolimod, which we are developing as a radiation countermeasure and as an immunotherapy for oncology and other indications.
We are aggressively pursuing development and commercialization of oncology drugs, orphan applications, and a radiation countermeasure.
Enrollment is open for our therapeutic clinical trials for various indications with oncology drug candidates in the pipeline.